Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multuple myeloma patients

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F12%3A33140652" target="_blank" >RIV/61989592:15110/12:33140652 - isvavai.cz</a>
Alternative codes found
RIV/00098892:_____/12:#0000263
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multuple myeloma patients
Original language description
In a cohort of 169 patients with multiple myeloma, treated at our department with bortezomib-based chemotherapy, we assessed the incidence of herpes zoster reactivation in patients with and without low dose acyclovir (200mg once daily) prophylaxis. In 78patients ( 46%) without any prophylaxis, herpes zoster occured in 21 cases (27%). In 92 patients (54%) with low-dose acyclovir prophylaxis there was only one case of herpes zoster in a patient with skipped medication. Most patients with herpes zoster underwent the reactivation within the first three cycles of the treatment. Low-dose acyclovir in multiple myeloma patients treated with bortezomib creates a sufficient prophylaxis of herpes zoster reactivation.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Project
<a href="/en/project/NT12451" target="_blank" >NT12451: The significance of the analysis of the pairs of immunoglobulin heavy/light chains by Hevylite TM in monoclonal gammopathy of undetermined significance and multiple myeloma</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)